{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T01:40:25Z","timestamp":1758678025335,"version":"3.44.0"},"publisher-location":"Cham","reference-count":72,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783031945397"},{"type":"electronic","value":"9783031945403"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-94540-3_14","type":"book-chapter","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T14:51:28Z","timestamp":1756565488000},"page":"351-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Technological Advances Applied to TB Vaccine Development: How Can AI Contribute to the Development of New TB Vaccines?"],"prefix":"10.1007","author":[{"given":"Jo\u00e3o Santos","family":"Pereira","sequence":"first","affiliation":[]},{"given":"David","family":"Pires","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"14_CR1","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva; 2023."},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","volume":"22","author":"C Lange","year":"2022","unstructured":"Lange C, Aaby P, Behr MA, Donald PR, Kaufmann SHE, Netea MG, Mandalakas AM. 100 years of Mycobacterium bovis bacille Calmette-Gu\u00e9rin. Lancet Infect Dis. 2022;22:e2\u2013e12.","journal-title":"Lancet Infect Dis"},{"key":"14_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583077","volume":"11","author":"M Brisse","year":"2020","unstructured":"Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11:583077.","journal-title":"Front Immunol"},{"key":"14_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2024.106998","volume":"224","author":"DB Olawade","year":"2024","unstructured":"Olawade DB, Teke J, Fapohunda O, Weerasinghe K, Usman SO, Ige AO, Clement David-Olawade A. Leveraging artificial intelligence in vaccine development: a narrative review. J Microbiol Methods. 2024;224:106998.","journal-title":"J Microbiol Methods"},{"key":"14_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01479","volume":"9","author":"SA Valkenburg","year":"2018","unstructured":"Valkenburg SA, Leung NHL, Bull MB, Yan L, Li APY, Poon LLM, Cowling BJ. The hurdles from bench to bedside in the realization and implementation of a universal influenza vaccine. Front Immunol. 2018;9:390431.","journal-title":"Front Immunol"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1016\/j.vaccine.2016.02.079","volume":"34","author":"TG Evans","year":"2016","unstructured":"Evans TG, Schrager L, Thole J. Status of vaccine research and development of vaccines for tuberculosis. Vaccine. 2016;34:2911\u20134.","journal-title":"Vaccine"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coi.2014.01.009","volume":"28","author":"SHE Kaufmann","year":"2014","unstructured":"Kaufmann SHE, Juliana McElrath M, Lewis DJM, Del Giudice G. Challenges and responses in human vaccine development. Curr Opin Immunol. 2014;28:18\u201326.","journal-title":"Curr Opin Immunol"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/jpm13030408","volume":"13","author":"F Jiang","year":"2023","unstructured":"Jiang F, Sun T, Cheng P, Wang J, Gong W. A summary on tuberculosis vaccine development\u2014where to go? J Pers Med. 2023;13:408.","journal-title":"J Pers Med"},{"key":"14_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.tips.2011.06.003","volume":"32","author":"AM Checkley","year":"2011","unstructured":"Checkley AM, McShane H. Tuberculosis vaccines: progress and challenges. Trends Pharmacol Sci. 2011;32:601\u20136.","journal-title":"Trends Pharmacol Sci"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41541-023-00750-7","volume":"8","author":"R Lai","year":"2023","unstructured":"Lai R, Ogunsola AF, Rakib T, Behar SM. Key advances in vaccine development for tuberculosis-success and challenges. NPJ Vaccines. 2023;8:158.","journal-title":"NPJ Vaccines"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5114\/ceji.2017.69362","volume":"42","author":"MM Usman","year":"2017","unstructured":"Usman MM, Ismail S, Teoh TC. Vaccine research and development: tuberculosis as a global health threat. Cent Eur J Immunol. 2017;42:196\u2013204.","journal-title":"Cent Eur J Immunol"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"ftw016","DOI":"10.1093\/femspd\/ftw016","volume":"74","author":"HM Dockrell","year":"2016","unstructured":"Dockrell HM. Towards new TB vaccines: what are the challenges? Pathog Dis. 2016;74:ftw016.","journal-title":"Pathog Dis"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58:470\u201380.","journal-title":"Clin Infect Dis"},{"key":"14_CR14","doi-asserted-by":"publisher","unstructured":"Wang H, Wang S, Fang R, Li X, Xing J, Li Z, Song N. Enhancing TB vaccine efficacy: current progress on vaccines, adjuvants and immunization strategies. Vaccines (Basel). 2023; https:\/\/doi.org\/10.3390\/vaccines12010038.","DOI":"10.3390\/vaccines12010038"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/microorganisms7080255","volume":"7","author":"E Stewart","year":"2019","unstructured":"Stewart E, Triccas JA, Petrovsky N. Adjuvant strategies for more effective tuberculosis vaccine immunity. Microorganisms. 2019;7:255. https:\/\/doi.org\/10.3390\/microorganisms7080255.","journal-title":"Microorganisms"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"895020","DOI":"10.3389\/FIMMU.2022.895020","volume":"13","author":"Z Hu","year":"2022","unstructured":"Hu Z, Lu SH, Lowrie DB, Fan XY. Research advances for virus-vectored tuberculosis vaccines and latest findings on tuberculosis vaccine development. Front Immunol. 2022;13:895020. https:\/\/doi.org\/10.3389\/FIMMU.2022.895020.","journal-title":"Front Immunol"},{"key":"14_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","volume":"112","author":"E Oude Blenke","year":"2023","unstructured":"Oude Blenke E, \u00d6rnskov E, Sch\u00f6neich C, Nilsson GA, Volkin DB, Mastrobattista E, Almarsson \u00d6, Crommelin DJA. The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case. J Pharm Sci. 2023;112:386\u2013403.","journal-title":"J Pharm Sci"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/VACCINES9091033","volume":"9","author":"MN Uddin","year":"2021","unstructured":"Uddin MN, Roni MA. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines (Basel). 2021;9:1033. https:\/\/doi.org\/10.3390\/VACCINES9091033.","journal-title":"Vaccines (Basel)"},{"issue":"Suppl 1","key":"14_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/nm1218","volume":"11","author":"BC Buckland","year":"2005","unstructured":"Buckland BC. The process development challenge for a new vaccine. Nat Med. 2005;11(Suppl 1):16\u20139.","journal-title":"Nat Med"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1586\/14760584.8.2.227","volume":"8","author":"B Metz","year":"2009","unstructured":"Metz B, Van Den Dobbelsteen G, Van Els C, Van Der Gun J, Levels L, Van Der Pol L, Rots N, Kersten G. Quality-control issues and approaches in vaccine development. Expert Rev Vaccines. 2009;8:227\u201338.","journal-title":"Expert Rev Vaccines"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.12688\/F1000RESEARCH.13588.1","volume":"7","author":"HA Fletcher","year":"2018","unstructured":"Fletcher HA, Voss G, Casimiro D, Neyrolles O, Williams A, Kaufmann SHE, McShane H, Hatherill M. Progress and challenges in TB vaccine development. F1000Res. 2018;7:199. https:\/\/doi.org\/10.12688\/F1000RESEARCH.13588.1.","journal-title":"F1000Res"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1517\/14712598.4.9.1493","volume":"4","author":"MJ Brennan","year":"2004","unstructured":"Brennan MJ, Morris SL, Sizemore CF. Tuberculosis vaccine development: research, regulatory and clinical strategies. Expert Opin Biol Ther. 2004;4:1493\u2013504.","journal-title":"Expert Opin Biol Ther"},{"key":"14_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4314\/ahs.v22i2.6S","volume":"22","author":"P Naluyima","year":"2022","unstructured":"Naluyima P, Mwesigwa B, Tindikahwa A, Mugamba S, Ssensamba JT, Musingye E, Mirembe G, Kibuuka H, Wabwire-Mangen F. Developing capacity for implementation and evaluation of vaccine trials in Uganda: perspective of the Makerere University Walter Reed Project. Afr Health Sci. 2022;22:34\u201341.","journal-title":"Afr Health Sci"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.healthpol.2021.03.013","volume":"125","author":"R Forman","year":"2021","unstructured":"Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. COVID-19 vaccine challenges: what have we learned so far and what remains to be done? Health Policy. 2021;125:553.","journal-title":"Health Policy"},{"issue":"Suppl 2","key":"14_CR25","doi-asserted-by":"publisher","first-page":"B129","DOI":"10.1016\/j.vaccine.2013.01.058","volume":"31","author":"NK Arora","year":"2013","unstructured":"Arora NK, Lal AA, Hombach JM, Santos JI, Bhutta ZA, Sow SO, Greenwood B. The need for targeted implementation research to improve coverage of basic vaccines and introduction of new vaccines. Vaccine. 2013;31(Suppl 2):B129\u201336.","journal-title":"Vaccine"},{"key":"14_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/jppr.1862","volume":"53","author":"S Belton","year":"2023","unstructured":"Belton S, Schultz R, Speare T. Vaccine cold chain in remote environments: culturally appropriate training opportunities, an evaluation. J Pharm Pract Res. 2023;53:147\u201351.","journal-title":"J Pharm Pract Res"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"1085319","DOI":"10.3389\/FPUBH.2022.1085319\/PDF","volume":"10","author":"S Eckermann","year":"2022","unstructured":"Eckermann S. Globally optimal trial design and risk sharing arrangements are key to avoiding opportunity costs of delay and enabling equitable, feasible and effective global vaccine research and implementation in current or future pandemics. Front Public Health. 2022;10:1085319. https:\/\/doi.org\/10.3389\/FPUBH.2022.1085319\/PDF.","journal-title":"Front Public Health"},{"key":"14_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11673-019-09954-w","volume":"17","author":"RF Boulanger","year":"2020","unstructured":"Boulanger RF, Komparic A, Dawson A, Upshur REG, Silva DS. Developing and implementing new TB technologies: key informants\u2019 perspectives on the ethical challenges. J Bioeth Inq. 2020;17:65\u201373.","journal-title":"J Bioeth Inq"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nrd2159","volume":"5","author":"JL Deen","year":"2006","unstructured":"Deen JL, Clemens JD. Issues in the design and implementation of vaccine trials in less developed countries. Nat Rev Drug Discov. 2006;5:932\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/COH.0000000000000815","volume":"18","author":"K Chinyenze","year":"2023","unstructured":"Chinyenze K, Nduati E, Muturi-Kioi V. Accelerating HIV vaccine development through meaningful engagement of local scientists and communities. Curr Opin HIV AIDS. 2023;18:284\u20139.","journal-title":"Curr Opin HIV AIDS"},{"key":"14_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000076","volume":"2","author":"PT Pelzer","year":"2022","unstructured":"Pelzer PT, Seeley J, Sun FY, et al. Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines. PLoS Global Public Health. 2022;2:e0000076.","journal-title":"PLoS Global Public Health"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"i7","DOI":"10.1093\/oodh\/oqae005","volume":"2","author":"N do Nascimento","year":"2024","unstructured":"do Nascimento N, Sichel A, Waugaman A, et al. Learning from digital health investments during COVID-19 vaccine program implementation: a research collaboration and theory of change. Oxford Open Digital Health. 2024;2:i7\u2013i15.","journal-title":"Oxford Open Digital Health"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","volume":"177","author":"V Prasad","year":"2017","unstructured":"Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177:1569\u201375.","journal-title":"JAMA Intern Med"},{"issue":"7873","key":"14_CR34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139.","journal-title":"Nature"},{"issue":"8016","key":"14_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493\u2013500.","journal-title":"Nature"},{"key":"14_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/PHARMACEUTICS15020654","volume":"15","author":"L Saldanha","year":"2023","unstructured":"Saldanha L, Langel \u00dc, Vale N. In Silico studies to support vaccine development. Pharmaceutics. 2023;15:654. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15020654.","journal-title":"Pharmaceutics"},{"key":"14_CR37","first-page":"1","volume":"21","author":"B Sarkar","year":"2021","unstructured":"Sarkar B, Ullah MA, Araf Y, Islam NN, Zohora US. Immunoinformatics-guided designing and in silico analysis of epitope-based polyvalent vaccines against multiple strains of human coronavirus (HCoV). Expert Rev Vaccines. 2021;21:1.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"14_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-34464-6","volume":"14","author":"W Han","year":"2023","unstructured":"Han W, Chen N, Xu X, et al. Predicting the antigenic evolution of SARS-COV-2 with deep learning. Nat Commun. 2023;14(1):1\u201314.","journal-title":"Nat Commun"},{"key":"14_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-023-06617-0","volume":"622","author":"NN Thadani","year":"2023","unstructured":"Thadani NN, Gurev S, Notin P, Youssef N, Rollins NJ, Ritter D, Sander C, Gal Y, Marks DS. Learning from prepandemic data to forecast viral escape. Nature. 2023;622:818\u201325.","journal-title":"Nature"},{"key":"14_CR40","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells11071182","volume":"11","author":"M Aileni","year":"2022","unstructured":"Aileni M, Rohela GK, Jogam P, Soujanya S, Zhang B. Biotechnological perspectives to combat the COVID-19 pandemic: precise diagnostics and inevitable vaccine paradigms. Cells. 2022;11:1182.","journal-title":"Cells"},{"key":"14_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14383","volume":"103","author":"V Saravanan","year":"2024","unstructured":"Saravanan V, Chagaleti BK, Narayanan PL, et al. Discovery and development of COVID-19 vaccine from laboratory to clinic. Chem Biol Drug Des. 2024;103:e14383.","journal-title":"Chem Biol Drug Des"},{"key":"14_CR42","unstructured":"International Pandemic Preparedness Secretariat. 100 days mission \u2013 implementation report 2023. London; 2024."},{"key":"14_CR43","doi-asserted-by":"publisher","first-page":"e1012131","DOI":"10.1371\/JOURNAL.PCBI.1012131","volume":"20","author":"J Wistuba-Hamprecht","year":"2024","unstructured":"Wistuba-Hamprecht J, Reuter B, Fendel R, Hoffman SL, Campo JJ, Felgner PL, Kremsner PG, Mordm\u00fcller B, Pfeifer N. Machine learning prediction of malaria vaccine efficacy based on antibody profiles. PLoS Comput Biol. 2024;20:e1012131. https:\/\/doi.org\/10.1371\/JOURNAL.PCBI.1012131.","journal-title":"PLoS Comput Biol"},{"key":"14_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/bioengineering11020185","volume":"11","author":"DN Kim","year":"2024","unstructured":"Kim DN, McNaughton AD, Kumar N. Leveraging artificial intelligence to expedite antibody design and enhance antibody\u2013antigen interactions. Bioengineering. 2024;11:185.","journal-title":"Bioengineering"},{"issue":"1","key":"14_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-73371-y","volume":"10","author":"A Singh","year":"2020","unstructured":"Singh A, Thakur M, Sharma LK, Chandra K. Designing a multi-epitope peptide based vaccine against SARS-CoV-2. Sci Rep. 2020;10(1):1\u201312.","journal-title":"Sci Rep"},{"key":"14_CR46","doi-asserted-by":"publisher","first-page":"a012476","DOI":"10.1101\/CSHPERSPECT.A012476","volume":"3","author":"I Delany","year":"2013","unstructured":"Delany I, Rappuoli R, Seib KL. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med. 2013;3:a012476. https:\/\/doi.org\/10.1101\/CSHPERSPECT.A012476.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"14_CR47","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.immuni.2010.09.017","volume":"33","author":"A Sette","year":"2010","unstructured":"Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity. 2010;33:530\u201341.","journal-title":"Immunity"},{"key":"14_CR48","doi-asserted-by":"publisher","first-page":"W671","DOI":"10.1093\/nar\/gkab279","volume":"49","author":"E Ong","year":"2021","unstructured":"Ong E, Cooke MF, Huffman A, Xiang Z, Wong MU, Wang H, Seetharaman M, Valdez N, He Y. Vaxign2: the second generation of the first web-based vaccine design program using reverse vaccinology and machine learning. Nucleic Acids Res. 2021;49:W671\u20138.","journal-title":"Nucleic Acids Res"},{"key":"14_CR49","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1093\/bioinformatics\/btaa119","volume":"36","author":"E Ong","year":"2020","unstructured":"Ong E, Wang H, Wong MU, Seetharaman M, Valdez N, He Y. Vaxign-ML: supervised machine learning reverse vaccinology model for improved prediction of bacterial protective antigens. Bioinformatics. 2020;36:3185\u201391.","journal-title":"Bioinformatics"},{"key":"14_CR50","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/VACCINES9101098\/S1","volume":"9","author":"B Teahan","year":"2021","unstructured":"Teahan B, Ong E, Yang Z. Identification of mycobacterium tuberculosis antigens with vaccine potential using a machine learning-based reverse vaccinology approach. Vaccines (Basel). 2021;9:1098. https:\/\/doi.org\/10.3390\/VACCINES9101098\/S1.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"14_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-08506-4","volume":"12","author":"H Al Tbeishat","year":"2022","unstructured":"Al Tbeishat H. Novel in Silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications. Sci Rep. 2022;12(1):1\u201319.","journal-title":"Sci Rep"},{"key":"14_CR52","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1007\/s12010-023-04658-9","volume":"196","author":"AM Arega","year":"2024","unstructured":"Arega AM, Dhal AK, Pattanaik KP, Nayak S, Mahapatra RK. An immunoinformatics-based study of Mycobacterium tuberculosis region of difference-2 uncharacterized protein (Rv1987) as a potential subunit vaccine candidate for preliminary ex vivo analysis. Appl Biochem Biotechnol. 2024;196:2367\u201395.","journal-title":"Appl Biochem Biotechnol"},{"key":"14_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4826030","volume":"2017","author":"MS Hossain","year":"2017","unstructured":"Hossain MS, Azad AK, Chowdhury PA, Wakayama M. Computational identification and characterization of a promiscuous T-cell epitope on the extracellular protein 85B of Mycobacterium spp. for peptide-based subunit vaccine design. Biomed Res Int. 2017;2017:1. https:\/\/doi.org\/10.1155\/2017\/4826030.","journal-title":"Biomed Res Int"},{"key":"14_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/FIMMU.2019.00113","volume":"10","author":"M Dalsass","year":"2019","unstructured":"Dalsass M, Brozzi A, Medini D, Rappuoli R. Comparison of open-source reverse vaccinology programs for bacterial vaccine antigen discovery. Front Immunol. 2019;10:113. https:\/\/doi.org\/10.3389\/FIMMU.2019.00113.","journal-title":"Front Immunol"},{"key":"14_CR55","doi-asserted-by":"publisher","unstructured":"Kaushik R, Kant R, Christodoulides M. Artificial intelligence in accelerating vaccine development \u2013 current and future perspectives. Front Bacteriol. 2023; https:\/\/doi.org\/10.3389\/fbrio.2023.1258159.","DOI":"10.3389\/fbrio.2023.1258159"},{"key":"14_CR56","doi-asserted-by":"publisher","unstructured":"Yurina V, Adianingsih OR. Predicting epitopes for vaccine development using bioinformatics tools. 2022. https:\/\/doi.org\/10.1177\/25151355221100218.","DOI":"10.1177\/25151355221100218"},{"key":"14_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007219","volume":"15","author":"G Janson","year":"2019","unstructured":"Janson G, Grottesi A, Pietrosanto M, Ausiello G, Guarguaglini G, Paiardini A. Revisiting the \u201csatisfaction of spatial restraints\u201d approach of MODELLER for protein homology modeling. PLoS Comput Biol. 2019;15:e1007219.","journal-title":"PLoS Comput Biol"},{"key":"14_CR58","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","volume":"32","author":"M Andreatta","year":"2016","unstructured":"Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32:511\u20137.","journal-title":"Bioinformatics"},{"key":"14_CR59","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/imm.12889","volume":"154","author":"KK Jensen","year":"2018","unstructured":"Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B, Nielsen M. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154:394\u2013406.","journal-title":"Immunology"},{"key":"14_CR60","doi-asserted-by":"publisher","first-page":"1369890","DOI":"10.3389\/fimmu.2024.1369890","volume":"15","author":"AS Alawam","year":"2024","unstructured":"Alawam AS, Alwethaynani MS. Construction of an aerolysin-based multi-epitope vaccine against Aeromonas hydrophila: an in silico machine learning and artificial intelligence-supported approach. Front Immunol. 2024;15:1369890.","journal-title":"Front Immunol"},{"key":"14_CR61","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Ruth H, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785.","journal-title":"J Comput Chem"},{"key":"14_CR62","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1021\/acscentsci.6b00367","volume":"3","author":"H Altae-Tran","year":"2017","unstructured":"Altae-Tran H, Ramsundar B, Pappu AS, Pande V. Low data drug discovery with one-shot learning. ACS Cent Sci. 2017;3:283\u201393.","journal-title":"ACS Cent Sci"},{"key":"14_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10663","volume":"9","author":"M Goetz","year":"2024","unstructured":"Goetz M, Thotathil N, Zhao Z, Mitragotri S. Vaccine adjuvants for infectious disease in the clinic. Bioeng Transl Med. 2024;9:e10663.","journal-title":"Bioeng Transl Med"},{"key":"14_CR64","doi-asserted-by":"publisher","first-page":"1438030","DOI":"10.3389\/fimmu.2024.1438030","volume":"15","author":"WY Zhang","year":"2024","unstructured":"Zhang WY, Zheng XL, Coghi PS, Chen JH, Dong BJ, Fan XX. Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines. Front Immunol. 2024;15:1438030.","journal-title":"Front Immunol"},{"key":"14_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fenvs.2015.00080","volume":"3","author":"A Mayr","year":"2016","unstructured":"Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: toxicity prediction using deep learning. Front Environ Sci. 2016;3:167215.","journal-title":"Front Environ Sci"},{"key":"14_CR66","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/S12859-019-3045-5","volume":"20","author":"M Pennisi","year":"2019","unstructured":"Pennisi M, Russo G, Sgroi G, et al. Predicting the artificial immunity induced by RUTI\u00ae vaccine against tuberculosis using universal immune system simulator (UISS). BMC Bioinformatics. 2019;20:504. https:\/\/doi.org\/10.1186\/S12859-019-3045-5.","journal-title":"BMC Bioinformatics"},{"key":"14_CR67","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/S12859-020-03872-0","volume":"21","author":"G Russo","year":"2020","unstructured":"Russo G, Pennisi M, Fichera E, Motta S, Raciti G, Viceconti M, Pappalardo F. In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform. BMC Bioinformatics. 2020;21:527. https:\/\/doi.org\/10.1186\/S12859-020-03872-0.","journal-title":"BMC Bioinformatics"},{"key":"14_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bib\/bbab403","volume":"23","author":"G Russo","year":"2022","unstructured":"Russo G, Di Salvatore V, Sgroi G, Parasiliti Palumbo GA, Reche PA, Pappalardo F. A multi-step and multi-scale bioinformatic protocol to investigate potential SARS-CoV-2 vaccine targets. Brief Bioinform. 2022;23:1\u20139.","journal-title":"Brief Bioinform"},{"key":"14_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-023-05374-1","volume":"24","author":"G Russo","year":"2023","unstructured":"Russo G, Crispino E, Maleki A, Di Salvatore V, Stanco F, Pappalardo F. Beyond the state of the art of reverse vaccinology: predicting vaccine efficacy with the universal immune system simulator for influenza. BMC Bioinformatics. 2023;24:1\u201322.","journal-title":"BMC Bioinformatics"},{"key":"14_CR70","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/d41573-023-00118-5","volume":"22","author":"E Dolgin","year":"2023","unstructured":"Dolgin E. Personalized cancer vaccines pass first major clinical test. Nat Rev Drug Discov. 2023;22:607\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"14_CR71","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344.","journal-title":"Lancet"},{"issue":"7963","key":"14_CR72","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"}],"container-title":["Tuberculosis Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-94540-3_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T01:03:27Z","timestamp":1758675807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-94540-3_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031945397","9783031945403"],"references-count":72,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-94540-3_14","relation":{},"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"31 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}